Amlodipine and olmesartan Medoxomil

Amlodipine and olmesartan Medoxomil · AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 · Tablet · Oral · Ascend Laboratories, LLC

NDC 67877-0500-90 · 90 TABLET in 1 BOTTLE · ANDA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately. The price has fallen 35% in a year, to $0.2298 per unit — and generics that get this cheap tend to get abandoned rather than defended. 2 Class II recalls hit this product in the past year (Ascend Laboratories, LLC). Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built

Data sources

CMS NADAC (pharmacy acquisition, weekly)
CMS Part B ASP quarterly payment limits
CMS Maximum Fair Prices (IRA negotiated, NDC-level)
Medicare Part D Spending by Drug (data.cms.gov, name-matched)
VA FSS / Big4 federal contract prices (va.gov, twice monthly)
ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
California SB-17 WAC filings (list price, per package)

Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Pharmacies pay (NADAC)$0.2298per EAinvoice-surveyed acquisition cost · Aug 19, 2026
Medicaid generic ceiling (FUL)$0.2636per TABweighted avg manufacturer price $0.1506 · Aug 1, 2026115% of what pharmacies pay — higher than 67% of drugs with this benchmark

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 42571-0236-30) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built

Data sources

CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)

Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ

$0.4688per unit

middle half $0.2217–$0.7942 · 5,019 plans · Apr 1, 2026

Est. net of rebatesⓘ

≈ $0.4688

generic — rebates are minimal, so net ≈ gross

Coverage & restrictions

91%of plans cover it

tier 1 · prior auth 0% · step therapy 0% · qty limit 84%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 9 quarters since 2024.

NADAC price per unit

95 price points · per EA · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count

$6.89

#90 count

$20.68

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Supply fragility

33● Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

3 active manufacturers+10
Class I/II recall in past 12 months+15
price down 38% year over year+8

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.2%chance of a new FDA shortage posting for amlodipine and olmesartan medoxomil (oral solid) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market · 2 Class I/II recall(s) in 12 months

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Alkem Laboratories LimitedIndia
analysis · manufacture · pack

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application: ANDA209042
TE code: AB
Approval date: Aug 14, 2017
Patents / exclusivity: None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

Class II · OngoingJul 8, 2026
Ascend Laboratories, LLC — Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications
Class II · OngoingMay 5, 2026
Ascend Laboratories, LLC — Failed Dissolution Specifications: Olmesartan Medoxomil content below specifications
Class II · OngoingJul 21, 2025
Ascend Laboratories, LLC — Failed Dissolution Specifications: low dissolution results

Manufacturers of Amlodipine and olmesartan Medoxomil (Tablet)

Labeler	Strength	First seen	Last seen
Ascend Laboratories, LLC	AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1	Jul 15, 2026	Sep 2, 2026
Ascend Laboratories, LLC	AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1	Jul 15, 2026	Sep 2, 2026
Ascend Laboratories, LLC	AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1	Jul 15, 2026	Sep 2, 2026
Ascend Laboratories, LLC	AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1	Jul 15, 2026	Sep 2, 2026
Bryant Ranch Prepack	AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1	Jul 15, 2026	Sep 2, 2026
Micro Labs Limited	AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1	Jul 15, 2026	Sep 2, 2026
Micro Labs Limited	AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1	Jul 15, 2026	Sep 2, 2026
Micro Labs Limited	AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1	Jul 15, 2026	Sep 2, 2026
Micro Labs Limited	AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1	Jul 15, 2026	Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Amlodipine and olmesartan Medoxomil — NDC 67877-0500-90," retrieved September 3, 2026, https://drugdashboards.com/drug/67877050090.

Free to cite with attribution — see how the data is put together.